This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary IL-4R Therapeutic Antibody Development
Background of IL-4R
IL-4R functions by regulating the immune system, influencing cell behavior, and mediating inflammatory responses. In the field of veterinary medicine, the potential of IL-4R as a therapeutic target is increasingly recognized. BioVenic has established the platform for veterinary IL-4R therapeutic antibody development, relying on emerging technologies and extensive experience, providing full-process services to aid in the development of veterinary IL-4R antibodies.
Background of IL-4R
| Full Name | Interleukin 4 receptor |
|---|---|
| Aliases | CD124, IL4R. |
| Target Profile | IL-4R is a transmembrane protein composed of an extracellular binding domain and a transmembrane domain. As the receptor for IL-4 and IL-13, IL-4R is expressed in various cell types, including T cells, B cells, macrophages, and mast cells. Activation of IL-4R promotes the differentiation of Th2 cells, affects antibody class switching, enhances cell-mediated immune responses, and plays a crucial role in the development of allergic diseases. |
MoA of IL-4R
IL-4R exists in two forms: Type I IL-4R consists of the IL-4Rα subunit combined with the γ subunit, while Type II IL-4R comprises the IL-4Rα subunit combined with the IL-13Rα1 subunit. This structural diversity allows IL-4R to effectively bind with IL-4 and IL-13, performing similar biological functions. When IL-4 binds to the IL-4Rα subunit, it triggers conformational changes within the receptor, activating associated tyrosine kinases such as JAK1/JAK3 and TYK2, further leading to the phosphorylation of STAT6. Activated STAT6 forms dimers and moves to the nucleus to promote transcription of IL-4-sensitive genes. In addition to the STAT6 pathway, activation of IL-4R can also stimulate a series of gene expressions within the cell through other pathways, such as the PI3K/AKT and MAPK signaling pathways, thereby affecting cell proliferation, differentiation, and immune responses.
Fig.1 Schematic diagram of IL-4R structure and signaling.1
Application in Veterinary Therapeutics
IL-4 and IL-13 are key cytokines that induce and maintain type II inflammatory responses, closely associated with numerous allergic diseases, such as atopic dermatitis commonly observed in dogs. Antibodies targeting IL-4R can effectively modulate the activity of these cytokines, thereby possessing the potential to alleviate clinical symptoms of related diseases. In treating allergic skin conditions like atopic dermatitis, IL-4R antibodies can reduce the release of inflammatory mediators, decreasing skin redness, itching, and lesions. Additionally, in asthma and other respiratory allergic diseases, these antibodies can lessen airway inflammation, improving respiratory functions in animals. Beyond allergic diseases, IL-4R antibodies show promise in treating immune-mediated conditions, such as certain autoimmune skin diseases and arthritis. In these cases, IL-4R antibodies aid in controlling disease progression and symptom relief by modulating immune responses.
Veterinary IL-4R Therapeutic Antibody Development Services
BioVenic specializes in providing comprehensive veterinary IL-4R therapeutic antibody development services. Utilizing our integrated technology platform, we assist in creating therapeutic antibodies that specifically bind and regulate IL-4R, aiming to provide safer and more effective treatment options for companion animals. Our service also includes detailed antibody characterization and precise engineering design to ensure that our developed therapeutic antibodies possess excellent affinity and safety.
Please click the link below for more information about our veterinary IL-4R therapeutic antibody development services.
Why Choose Us?
BioVenic provides comprehensive veterinary therapeutic antibody development services, covering from gene synthesis and animal immunization to antibody production and purification.
We focus on providing targeted solutions based on the specific needs of different animal species, offering species-specific antibody development to meet the needs of companion animals.
Throughout our service process, we emphasize strict quality control to ensure the developed therapeutic antibodies have optimal purity and stability.
As a vital immune modulator in companion animals, targeting IL-4R with therapeutic antibodies regulates immune responses, holding the potential to alleviate symptoms and improve the quality of life in companion animals. BioVenic provides veterinary IL-4R therapeutic antibody development services, aiding you in bringing more treatment options and better outcomes for companion animals. If you have development needs, please do not hesitate to contact us!
Reference
- Druszczyńska, Magdalena, et al. "Cytokine receptors—regulators of antimycobacterial immune response." International Journal of Molecular Sciences 23.3 (2022): 1112.